Federal Register Notice: FDA’s Psychopharmacologic Drugs Advisory Committee will meet 6/16, from 8 a.m. to 5 p.m. at the Marriott Washingtonian Center, Gaithersburg, MD. On 6/16, the committee will discuss the white blood cell (WBC) monitoring schedule for patients being treated long-term with clozapine. Currently, the WBC monitoring schedule is weekly for the first six months of continuous therapy and biweekly thereafter. The committee will consider the question of whether the frequency of WBC monitoring can be diminished further following some period of biweekly monitoring. Contact JayneE. Peterson, (301)827-7001. To view this notice, click here.
